Related news from
Wed, 24 Apr 2024 14:15:33 +0000	Does Neurocrine, The No. 1 Biotech Stock, Have The Next Ketamine On Its Hands? Top-notch biotech stock Neurocrine surged Tuesday after analysts suggested the company's depression treatment could rival ketamine.
Wed, 24 Apr 2024 14:01:38 +0000	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wed, 24 Apr 2024 12:30:00 +0000	Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of WHAT THE C@H?!, an educational initiative that aims to close the gap in the need for helpful information about congenital adrenal hyperplasia (CAH) and acknowledges the frustrations and challenges experienced by the community in managing the condition.
Tue, 23 Apr 2024 11:22:00 +0000	Neurocrine scores surprise win with depression drug Shares of the biotech rose about 5% after a medicine licensed from Takeda hit the main and key secondary goals of a mid-stage study focused on major depressive disorder.
Tue, 23 Apr 2024 11:00:00 +0000	Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its Phase 2 SAVITRI™ study. This randomized, double-blind, placebo-controlled dose-finding study assessed the efficacy and safety of NBI-1065845 in adult subjects with major depressive disorder (MDD). NBI-1065845 is an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator (PAM) in development as a potential treatment for patients with MDD who have not be
Mon, 22 Apr 2024 15:10:59 +0000	10 Best Performing Biotech ETFs in 2024 In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for […]
Tue, 16 Apr 2024 20:01:00 +0000	Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Sentia Medical Sciences Inc. today announced that they have further extended a research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) aimed at discovering novel, long-acting corticotropin-releasing factor (CRF) receptor antagonist peptide therapeutics. The collaboration will continue to leverage Sentia’s proprietary peptide-based platform and Neurocrine’s drug development expertise in CRF biology to develop and commercialize medicine
Wed, 10 Apr 2024 20:01:00 +0000	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on May 1, 2024.
Tue, 09 Apr 2024 11:37:17 +0000	11 Best Biotech ETFs To Buy In this article, we discuss 11 best biotech ETFs to buy. If you want to skip our discussion on the biotech industry, head over to 5 Best Biotech ETFs To Buy. The new era in biotech is defined by the convergence of biology, data, and artificial intelligence. According to The Journal of mHealth, the focus […]
Wed, 03 Apr 2024 14:36:50 +0000	Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Recent Performance Tethered To Its Attractive Financial Prospects? Neurocrine Biosciences' (NASDAQ:NBIX) stock is up by 4.9% over the past month. Given its impressive performance, we...
Wed, 03 Apr 2024 12:30:00 +0000	Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder. NBI-1070770 is a novel, selective, and orally active, negative allosteric modulator (NAM) of the NR2B subunit-containing N-methyl-D-aspartate (NMDA NR2B) receptor.
Thu, 28 Mar 2024 12:30:00 +0000	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1065890 in healthy adult participants. NBI-1065890 is an investigational, oral, selective inhibitor of the vesicular monoamine transporter-2 (VMAT2) for the potential treatment of certain neurological and neuropsychiatric conditions.
Sat, 23 Mar 2024 12:00:50 +0000	S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind S&P 500 stocks DexCom, Blackstone and Royal Caribbean lead five stocks around buy points after Fed chief Jerome Powell helped buoy markets.
Fri, 22 Mar 2024 11:25:01 +0000	Dow Jones Futures: Apple Sour, But These 11 Stocks Flash Buy Signals; FedEx Soars The major indexes faded from record highs as Apple fell on a DOJ lawsuit. But many stocks flashed buy signals. Lululemon, FedEx and Nike reported late.
Sat, 16 Mar 2024 12:00:19 +0000	AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base Artificial intelligence plays HubSpot and Arista Networks are among five stocks near buy points with big market news on tap.
Sat, 16 Mar 2024 05:23:34 +0000	Neurocrine Biosciences Inc's Chief Regulatory Officer Ingrid Delaet Sells 3,000 Shares Neurocrine Biosciences Inc (NASDAQ:NBIX), a company specializing in the development of treatments for neurological and endocrine-related diseases and disorders, has reported an insider sale according to a recent SEC filing.
Sat, 16 Mar 2024 05:23:33 +0000	Director Richard Pops Sells 23,200 Shares of Neurocrine Biosciences Inc (NBIX) Director Richard Pops has sold 23,200 shares of Neurocrine Biosciences Inc (NASDAQ:NBIX) on March 13, 2024, according to a recent SEC filing.
Fri, 15 Mar 2024 14:00:01 +0000	Neurocrine Biosciences Is Pioneering Therapies for Neurological Disorders A closer look at one of the leaders in the global tardive dyskinesia treatment market
Wed, 13 Mar 2024 05:26:05 +0000	Director Richard Pops Sells Shares of Neurocrine Biosciences Inc (NBIX) Richard Pops, Director of Neurocrine Biosciences Inc (NASDAQ:NBIX), executed a sale of 1,800 shares in the company on March 11, 2024, according to a recent SEC Filing.
Mon, 11 Mar 2024 20:01:00 +0000	Neurocrine Biosciences to Participate at Virtual Investor Conferences in March Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming virtual investor conferences in March.